BACKGROUND: Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated withatorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the rate of event reduction was greater in carriers of the Trp719Arg variant in kinesin family member 6 protein (KIF6) than in noncarriers. We assessed the cost effectiveness of testing for the KIF6 variant followed by targeted statin therapy (KIF6 Testing) versus not testing patients (No Test) and treating them with P40 or A80 in the USA from a payer perspective. METHODS: A Markov model was developed in which 2-year event rates from PROVE IT were extrapolated over a lifetime horizon. Costs and utilities were derived from published literature. All costs were in 2010 US dollars except the cost of A80, which was in 2012 US dollars because the generic formulation was available in 2012. Expected costs and quality-adjusted life-years (QALYs) were estimated for each strategy over a lifetime horizon. RESULTS:Lifetime costs were US$31,700; US$37,100 and US$41,300 for No Test P40, KIF6 Testing and No Test A80 strategies, respectively. The No Test A80 strategy was associated with more QALYs (9.71) than the KIF6 Testing (9.69) and No Test P40 (9.57) strategies. No Test A80 had an incremental cost-effectiveness ratio (ICER) of US$232,100 per QALY gained compared with KIF6 Testing. KIF6 Testing had an ICER of US$45,300 per QALY compared with No Test P40. CONCLUSIONS: Testing ACS patients for KIF6 carrier status may be a cost-effective strategy at commonly accepted thresholds. Treating all patients with A80 is more expensive than treating patients on the basis of KIF6 results, but the modest gain in QALYs is achieved at a cost/QALY that is generally considered unacceptable compared with the KIF6 Testing strategy. Compared with treating all patients with P40, the KIF6 Testing strategy had an ICER below US$50,000 per QALY. The conclusions from this study are sensitive to the price of generic A80 and the effect on adherence of knowing KIF6 carrier status. The results were based on a post hoc substudy of the PROVE IT trial, which was not designed to test the effectiveness of KIF6 testing.
RCT Entities:
BACKGROUND: Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the rate of event reduction was greater in carriers of the Trp719Arg variant in kinesin family member 6 protein (KIF6) than in noncarriers. We assessed the cost effectiveness of testing for the KIF6 variant followed by targeted statin therapy (KIF6 Testing) versus not testing patients (No Test) and treating them with P40 or A80 in the USA from a payer perspective. METHODS: A Markov model was developed in which 2-year event rates from PROVE IT were extrapolated over a lifetime horizon. Costs and utilities were derived from published literature. All costs were in 2010 US dollars except the cost of A80, which was in 2012 US dollars because the generic formulation was available in 2012. Expected costs and quality-adjusted life-years (QALYs) were estimated for each strategy over a lifetime horizon. RESULTS: Lifetime costs were US$31,700; US$37,100 and US$41,300 for No Test P40, KIF6 Testing and No Test A80 strategies, respectively. The No Test A80 strategy was associated with more QALYs (9.71) than the KIF6 Testing (9.69) and No Test P40 (9.57) strategies. No Test A80 had an incremental cost-effectiveness ratio (ICER) of US$232,100 per QALY gained compared with KIF6 Testing. KIF6 Testing had an ICER of US$45,300 per QALY compared with No Test P40. CONCLUSIONS: Testing ACS patients for KIF6 carrier status may be a cost-effective strategy at commonly accepted thresholds. Treating all patients with A80 is more expensive than treating patients on the basis of KIF6 results, but the modest gain in QALYs is achieved at a cost/QALY that is generally considered unacceptable compared with the KIF6 Testing strategy. Compared with treating all patients with P40, the KIF6 Testing strategy had an ICER below US$50,000 per QALY. The conclusions from this study are sensitive to the price of generic A80 and the effect on adherence of knowing KIF6 carrier status. The results were based on a post hoc substudy of the PROVE IT trial, which was not designed to test the effectiveness of KIF6 testing.
Authors: Olga A Iakoubova; Carmen H Tong; Charles M Rowland; Todd G Kirchgessner; Bradford A Young; Andre R Arellano; Dov Shiffman; Marc S Sabatine; Hannia Campos; Christopher J Packard; Marc A Pfeffer; Thomas J White; Eugene Braunwald; James Shepherd; James J Devlin; Frank M Sacks Journal: J Am Coll Cardiol Date: 2008-01-29 Impact factor: 24.094
Authors: Jemma C Hopewell; Sarah Parish; Robert Clarke; Jane Armitage; Louise Bowman; Jorg Hager; Mark Lathrop; Rory Collins Journal: J Am Coll Cardiol Date: 2011-03-31 Impact factor: 24.094
Authors: Nove K Kalia; Loren G Miller; Khurram Nasir; Roger S Blumenthal; Nisha Agrawal; Matthew J Budoff Journal: Atherosclerosis Date: 2005-07-26 Impact factor: 5.162
Authors: Themistocles L Assimes; Hilma Hólm; Sekar Kathiresan; Muredach P Reilly; Gudmar Thorleifsson; Benjamin F Voight; Jeanette Erdmann; Christina Willenborg; Dhananjay Vaidya; Changchun Xie; Chris C Patterson; Thomas M Morgan; Mary Susan Burnett; Mingyao Li; Mark A Hlatky; Joshua W Knowles; John R Thompson; Devin Absher; Carlos Iribarren; Alan Go; Stephen P Fortmann; Stephen Sidney; Neil Risch; Hua Tang; Richard M Myers; Klaus Berger; Monika Stoll; Svati H Shah; Gudmundur Thorgeirsson; Karl Andersen; Aki S Havulinna; J Enrique Herrera; Nauder Faraday; Yoonhee Kim; Brian G Kral; Rasika A Mathias; Ingo Ruczinski; Bhoom Suktitipat; Alexander F Wilson; Lisa R Yanek; Lewis C Becker; Patrick Linsel-Nitschke; Wolfgang Lieb; Inke R König; Christian Hengstenberg; Marcus Fischer; Klaus Stark; Wibke Reinhard; Janina Winogradow; Martina Grassl; Anika Grosshennig; Michael Preuss; Stefan Schreiber; H-Erich Wichmann; Christa Meisinger; Jean Yee; Yechiel Friedlander; Ron Do; James B Meigs; Gordon Williams; David M Nathan; Calum A MacRae; Liming Qu; Robert L Wilensky; William H Matthai; Atif N Qasim; Hakon Hakonarson; Augusto D Pichard; Kenneth M Kent; Lowell Satler; Joseph M Lindsay; Ron Waksman; Christopher W Knouff; Dawn M Waterworth; Max C Walker; Vincent E Mooser; Jaume Marrugat; Gavin Lucas; Isaac Subirana; Joan Sala; Rafael Ramos; Nicola Martinelli; Oliviero Olivieri; Elisabetta Trabetti; Giovanni Malerba; Pier Franco Pignatti; Candace Guiducci; Daniel Mirel; Melissa Parkin; Joel N Hirschhorn; Rosanna Asselta; Stefano Duga; Kiran Musunuru; Mark J Daly; Shaun Purcell; Sandra Eifert; Peter S Braund; Benjamin J Wright; Anthony J Balmforth; Stephen G Ball; Willem H Ouwehand; Panos Deloukas; Michael Scholz; Francois Cambien; Andreas Huge; Thomas Scheffold; Veikko Salomaa; Domenico Girelli; Christopher B Granger; Leena Peltonen; Pascal P McKeown; David Altshuler; Olle Melander; Joseph M Devaney; Stephen E Epstein; Daniel J Rader; Roberto Elosua; James C Engert; Sonia S Anand; Alistair S Hall; Andreas Ziegler; Christopher J O'Donnell; John A Spertus; David Siscovick; Stephen M Schwartz; Diane Becker; Unnur Thorsteinsdottir; Kari Stefansson; Heribert Schunkert; Nilesh J Samani; Thomas Quertermous Journal: J Am Coll Cardiol Date: 2010-11-02 Impact factor: 24.094
Authors: James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald Journal: JAMA Date: 2004-08-30 Impact factor: 56.272
Authors: S L Charland; B C Agatep; V Herrera; B Schrader; F W Frueh; M Ryvkin; J Shabbeer; J J Devlin; H R Superko; E J Stanek Journal: Pharmacogenomics J Date: 2013-08-27 Impact factor: 3.550
Authors: Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240
Authors: Ye Zhu; Kristi M Swanson; Ricardo L Rojas; Zhen Wang; Jennifer L St Sauver; Sue L Visscher; Larry J Prokop; Suzette J Bielinski; Liewei Wang; Richard Weinshilboum; Bijan J Borah Journal: Genet Med Date: 2019-10-08 Impact factor: 8.822
Authors: Charles A Brunette; Olivia M Dong; Jason L Vassy; Morgan E Danowski; Nicholas Alexander; Ashley A Antwi; Kurt D Christensen Journal: J Pers Med Date: 2021-10-31
Authors: Viktor V Chirikov; Chris Walker; Jennifer M Stephens; Patricia Schepman; Richard Chambers; Mahmoud Bakir; Gregory W Poorman; Seema Haider; Mohammed Farghaly Journal: Clinicoecon Outcomes Res Date: 2021-05-19